D. E. Shaw & Co. Inc. Reduces Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

D. E. Shaw & Co. Inc. lessened its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 100.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,500 shares of the biotechnology company's stock after selling 11,389,239 shares during the quarter. D. E. Shaw & Co. Inc.'s holdings in Sarepta Therapeutics were worth $426,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of SRPT. Park Avenue Securities LLC bought a new stake in Sarepta Therapeutics during the 4th quarter valued at $205,000. Nisa Investment Advisors LLC increased its stake in Sarepta Therapeutics by 23.1% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,317 shares of the biotechnology company's stock valued at $160,000 after purchasing an additional 247 shares in the last quarter. Fifth Third Bancorp increased its stake in Sarepta Therapeutics by 219.7% during the 4th quarter. Fifth Third Bancorp now owns 1,832 shares of the biotechnology company's stock valued at $223,000 after purchasing an additional 1,259 shares in the last quarter. PFG Investments LLC increased its stake in Sarepta Therapeutics by 1.2% during the 4th quarter. PFG Investments LLC now owns 26,998 shares of the biotechnology company's stock valued at $3,283,000 after purchasing an additional 324 shares in the last quarter. Finally, Blue Trust Inc. increased its stake in Sarepta Therapeutics by 56.9% during the 4th quarter. Blue Trust Inc. now owns 891 shares of the biotechnology company's stock valued at $111,000 after purchasing an additional 323 shares in the last quarter. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT traded up $1.38 during trading on Thursday, hitting $38.61. 2,483,643 shares of the company's stock traded hands, compared to its average volume of 1,801,118. The stock has a market capitalization of $3.79 billion, a price-to-earnings ratio of 30.89 and a beta of 0.85. Sarepta Therapeutics, Inc. has a 12-month low of $34.10 and a 12-month high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The business has a 50 day moving average of $52.32 and a 200-day moving average of $92.86.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The firm had revenue of $744.86 million during the quarter, compared to analysts' expectations of $685.75 million. During the same period in the previous year, the company posted $0.73 earnings per share. The company's quarterly revenue was up 80.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on SRPT shares. Guggenheim decreased their price target on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Royal Bank of Canada reduced their target price on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a "sector perform" rating for the company in a research note on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research note on Wednesday, March 19th. Needham & Company LLC reduced their target price on shares of Sarepta Therapeutics from $183.00 to $125.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Finally, Oppenheimer reduced their target price on shares of Sarepta Therapeutics from $184.00 to $123.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Six analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Sarepta Therapeutics has an average rating of "Moderate Buy" and an average price target of $122.61.

Insider Transactions at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.70% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.